July 27, 2025

The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma : a proof of concept with mifamurtide

View Full Paper

Ask AI

Bookmark

Authors

RQRohan QuoniouCentre National de la Recherche Scientifique EBElisa Bortoli EMEmmanuel MoreauUniversité de Tours

Discussion

Member takes

Implication

Preclinical research reveals mifamurtide boosts chemotherapy effectiveness in chondrosarcoma, indicating new treatment strategies may improve outcomes.

Key Points

Combining mifamurtide with doxorubicin shows enhanced antitumoral efficacy in chondrosarcoma models.
Mifamurtide is found to increase chemosensitivity in specific chondrosarcoma spheroid cultures.
Targeting tumor-associated macrophages reveals potential for improving treatment success against chondrosarcoma.
Results support further exploration of immunomodulator and chemotherapy combinations in cancer therapy.

Cite This Study

Quoniou et al. (2025) studied this question.

synapsesocial.com/papers/689a0939e6551bb0af8ce770 https://doi.org/10.21203/rs.3.rs-6954396/v1

View Full Paper

Ask AI

Bookmark

Implication

Preclinical research reveals mifamurtide boosts chemotherapy effectiveness in chondrosarcoma, indicating new treatment strategies may improve outcomes.

The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma : a proof of concept with mifamurtide

Discussion

Member takes

Implication

Key Points

Cite This Study

The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma : a proof of concept with mifamurtide

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider